标题
Insight into the Evolving Role of PCSK9
作者
关键词
-
出版物
Metabolites
Volume 12, Issue 3, Pages 256
出版商
MDPI AG
发表日期
2022-03-21
DOI
10.3390/metabo12030256
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Barriers to prescribing proprotein convertase subtilisin‐kexin type 9 inhibitors after coronary revascularisation
- (2022) Jenny Nguy et al. INTERNAL MEDICINE JOURNAL
- The Impact of the COVID-19 Outbreak on Patients’ Adherence to PCSK9 Inhibitors Therapy
- (2022) Valentina Maria Caso et al. Journal of Clinical Medicine
- Role of Proprotein Convertase Subtilisin/Kexin Type 9 in the Pathogenesis of Graves’ Orbitopathy in Orbital Fibroblasts
- (2021) Ga Eun Lee et al. Frontiers in Endocrinology
- Inclisiran: First Approval
- (2021) Yvette N. Lamb DRUGS
- Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting
- (2021) Roberto Scicali et al. ACTA DIABETOLOGICA
- A Critical Review of the Efficacy and Safety of Inclisiran
- (2021) Jennifer Hardy et al. American Journal of Cardiovascular Drugs
- Reduced adrenal stress response in patients on PCSK9 inhibitor therapy
- (2021) Simon Meier et al. ATHEROSCLEROSIS
- The role of proprotein convertase subtilisin/kexin type-9 concentration and paraoxonase 1 activities in the blood of women with polycystic ovary syndrome
- (2021) Anna Bizoń et al. ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY
- Novel Therapeutical Approaches to Managing Atherosclerotic Risk
- (2021) Rosaria Vincenza Giglio et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Pleiotropic Effects of PCSK-9 Inhibitors
- (2021) Marcin Basiak et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- HCV virology and diagnosis
- (2021) Steven Roger et al. Clinics and Research in Hepatology and Gastroenterology
- PCSK9 promotes tumor growth by inhibiting tumor cell apoptosis in hepatocellular carcinoma
- (2021) Shi-Zhe Zhang et al. Experimental Hematology & Oncology
- PCSK9 and cancer: Rethinking the link
- (2021) Khadijeh Mahboobnia et al. BIOMEDICINE & PHARMACOTHERAPY
- Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways
- (2021) Vittoria Cammisotto et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Impact of high neutrophil-to-lymphocyte ratio on the cardiovascular benefit of PCSK9 inhibitors in familial hypercholesterolemia subjects with atherosclerotic cardiovascular disease: real-world data from two lipid units
- (2021) Roberto Scicali et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- The Effect of the PCSK9 Inhibitor Evolocumab on Aldosterone Secretion among High Cardiovascular Risk Patients: A Pilot Study
- (2021) Elena Izkhakov et al. Journal of Clinical Medicine
- Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
- (2021) Piotr Pęczek et al. Life-Basel
- The Multifaceted Biology of PCSK9
- (2021) Nabil G Seidah et al. ENDOCRINE REVIEWS
- Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia
- (2021) Yajnavalka Banerjee et al. Expert Opinion On Drug Safety
- A Systematic Approach to Assess the Activity and Classification of PCSK9 Variants
- (2021) Kepa B. Uribe et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Meta‐analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD
- (2021) Azita H. Talasaz et al. PHARMACOTHERAPY
- Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study
- (2021) Adam Goldman et al. European Journal of Preventive Cardiology
- Association of lipid-lowering drugs with COVID-19 outcomes from a Mendelian randomization study
- (2021) Wuqing Huang et al. eLife
- CRISPR Gene Editing in Lipid Disorders and Atherosclerosis: Mechanisms and Opportunities
- (2021) Harry E. Walker et al. Metabolites
- A New Potential Strategy for Acute Non-Alcoholic Steatohepatitis (NASH)
- (2021) Anupamjeet Kaur Sekhon et al. American Journal of Case Reports
- Circulating PCSK9 is associated with liver biomarkers and hepatic steatosis
- (2020) Martine Paquette et al. CLINICAL BIOCHEMISTRY
- Arterial stiffness improvement after adding on PCSK9 inhibitors or ezetimibe to high-intensity statins in patients with familial hypercholesterolemia: A Two–Lipid Center Real-World Experience
- (2020) Giuseppe Mandraffino et al. Journal of Clinical Lipidology
- Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome
- (2020) Gregory G. Schwartz et al. CIRCULATION
- Cognition After Lowering LDL-Cholesterol With Evolocumab
- (2020) Baris Gencer et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up
- (2020) Behnood Bikdeli et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis
- (2020) Robert P. Giugliano et al. STROKE
- Effect of PCSK-9 Inhibitors on Lipid-Rich Vulnerable Coronary Plaque Assessed by Near-Infrared Spectroscopy
- (2020) Hiroyuki Omori et al. JACC-Cardiovascular Imaging
- PCSK9 Regulates Nox2-Mediated Platelet Activation via CD36 Receptor in Patients with Atrial Fibrillation
- (2020) Vittoria Cammisotto et al. Antioxidants
- PCSK9Qβ-003 Vaccine Attenuates Atherosclerosis in Apolipoprotein E-Deficient Mice
- (2020) Danyu Wu et al. CARDIOVASCULAR DRUGS AND THERAPY
- Secretion of the epithelial sodium channel chaperone PCSK9 from the cortical collecting duct links sodium retention with hypercholesterolemia in nephrotic syndrome.
- (2020) Eduardo Molina-Jijon et al. KIDNEY INTERNATIONAL
- Retraction: Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2007621.
- (2020) Mandeep R. Mehra et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-inflammatory effects of non-statin low-density lipoprotein cholesterol-lowering drugs: an unused potential?
- (2020) Anders Hovland et al. SCANDINAVIAN CARDIOVASCULAR JOURNAL
- Evolocumab, a PCSK9‐Monoclonal Antibody, Rapidly Reverses Coronary Artery Endothelial Dysfunction in People Living With HIV and People With Dyslipidemia
- (2020) Thorsten M. Leucker et al. Journal of the American Heart Association
- Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review
- (2020) F. H. van Bruggen et al. Expert Review of Clinical Pharmacology
- Comparison of Serum PCSK9 Levels in Subjects with Normoglycemia, Impaired Fasting Glucose, and Impaired Glucose Tolerance
- (2020) Eugene Han et al. Endocrinology and Metabolism
- Endothelial dysfunction in COVID-19: Current findings and therapeutic implications
- (2020) Matthias P. Nägele et al. ATHEROSCLEROSIS
- Association of the rs562556 PCSK9 Gene Polymorphism with Reduced Mortality in Severe Malaria among Malian Children
- (2020) Olesya Fedoryak et al. Canadian Journal of Infectious Diseases & Medical Microbiology
- An Update on the Role of PCSK9 in Atherosclerosis
- (2020) Ece Yurtseven et al. Journal of Atherosclerosis and Thrombosis
- Dengue virus induces PCSK9 expression to alter antiviral responses and disease outcomes
- (2020) Esther Shuyi Gan et al. JOURNAL OF CLINICAL INVESTIGATION
- PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive Synopsis
- (2020) Qianyun Guo et al. Frontiers in Genetics
- PCSK9: Associated with cardiac diseases and their risk factors?
- (2020) Yanan Guo et al. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- Kidney-derived PCSK9—a new driver of hyperlipidemia in nephrotic syndrome?
- (2020) Ferruh Artunc KIDNEY INTERNATIONAL
- Statins and PCSK9 inhibitors: What is their role in coronavirus disease 2019?
- (2020) Fotios Barkas et al. MEDICAL HYPOTHESES
- Coming Back to Physiology: Extra Hepatic Functions of Proprotein Convertase Subtilisin/Kexin Type 9
- (2020) Klaus-Dieter Schlüter et al. Frontiers in Physiology
- Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: A single lipid center real-world experience
- (2020) Roberto Scicali et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial
- (2019) Michelle L. O'Donoghue et al. CIRCULATION
- Future perspectives of the pharmacological management of diabetic dyslipidemia
- (2019) Angelo Maria Patti et al. Expert Review of Clinical Pharmacology
- Role of PCSK9 in lipid metabolic disorders and ovarian dysfunction in polycystic ovary syndrome
- (2019) Meijiao Wang et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Association of Lowering Low‐Density Lipoprotein Cholesterol With Contemporary Lipid‐Lowering Therapies and Risk of Diabetes Mellitus: A Systematic Review and Meta‐Analysis
- (2019) Safi U. Khan et al. Journal of the American Heart Association
- Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome
- (2019) Hideki Yano et al. Journal of Cardiology
- PCSK9 inhibitor improves cardiac function and reduces infarct size in rats with ischaemia/reperfusion injury: Benefits beyond lipid‐lowering effects
- (2019) Siripong Palee et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Platelet function and activation markers in primary hypercholesterolemia treated with PCSK9 monoclonal antibody: a 12-month follow-up
- (2019) Cristina Barale et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9
- (2019) Charles A. German et al. BIODRUGS
- PCSK9 inhibitors and cardiovascular outcomes
- (2019) Daniel Steffens et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- PCSK9 inhibition as a novel therapeutic target for alcoholic liver disease
- (2019) Ji Soo Lee et al. Scientific Reports
- Lipid lowering and Alzheimer disease risk: A mendelian randomization study
- (2019) Dylan M. Williams et al. ANNALS OF NEUROLOGY
- Endocrine diseases as causes of secondary hyperlipidemia
- (2019) Łukasz Bułdak et al. Endokrynologia Polska
- Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects
- (2019) Marja-Riitta Taskinen et al. Journal of Clinical Lipidology
- Vaccine Against PCSK9 Improved Renal Fibrosis by Regulating Fatty Acid β‐Oxidation
- (2019) Danyu Wu et al. Journal of the American Heart Association
- PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages
- (2018) Zufeng Ding et al. CARDIOVASCULAR RESEARCH
- PCSK9 expression in the ischaemic heart and its relationship to infarct size, cardiac function, and development of autophagy
- (2018) Zufeng Ding et al. CARDIOVASCULAR RESEARCH
- Proteomic Biomarkers for Incident Aortic Stenosis Requiring Valvular Replacement
- (2018) Johan Ljungberg et al. CIRCULATION
- PCSK9: A potential regulator of apoE/apoER2 against inflammation in atherosclerosis?
- (2018) Xue-qin Bai et al. CLINICA CHIMICA ACTA
- Atherosclerosis and inflammation: overview and updates
- (2018) Glaucylara Reis Geovanini et al. CLINICAL SCIENCE
- Pleiotropic Anti-atherosclerotic Effects of PCSK9 Inhibitors From Molecular Biology to Clinical Translation
- (2018) Angelos D. Karagiannis et al. Current Atherosclerosis Reports
- Sexual Dysfunction, Cardiovascular Risk and Effects of Pharmacotherapy
- (2018) Konstantinos P. Imprialos et al. Current Vascular Pharmacology
- Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting
- (2018) BinBin Zheng-Lin et al. DRUGS
- PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor
- (2018) Lorenzo Da Dalt et al. EUROPEAN HEART JOURNAL
- Myeloid receptor CD36 is required for early phagocytosis of myocardial infarcts and induction of Nr4a1-dependent mechanisms of cardiac repair
- (2018) Shirley Dehn et al. FASEB JOURNAL
- Evaluation of PCSK9 levels and its genetic polymorphisms in women with polycystic ovary syndrome
- (2018) Luana B. Xavier et al. GENE
- PCSK9 and neurocognitive function: Should it be still an issue after FOURIER and EBBINGHAUS results?
- (2018) Massimo R. Mannarino et al. Journal of Clinical Lipidology
- Malaria severity: Possible influence of the E670G PCSK9 polymorphism: A preliminary case-control study in Malian children
- (2018) Charles Arama et al. PLoS One
- Contribution of lectin-like oxidized low-density lipoprotein receptor-1 and LOX-1 modulating compounds to vascular diseases
- (2018) Anja Hofmann et al. VASCULAR PHARMACOLOGY
- PCSK9 induces a pro-inflammatory response in macrophages
- (2018) Chiara Ricci et al. Scientific Reports
- Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population
- (2018) Matthieu Wargny et al. ATHEROSCLEROSIS
- Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial
- (2018) Konstantinos C. Koskinas et al. CLINICAL CARDIOLOGY
- PCSK9 inhibitors: clinical evidence and implementation
- (2018) Marc S. Sabatine Nature Reviews Cardiology
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia
- (2018) Pragyi Shrestha et al. CELLULAR SIGNALLING
- PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia
- (2017) Sophie J. Bernelot Moens et al. EUROPEAN HEART JOURNAL
- No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data
- (2017) Philip D Harvey et al. EUROPEAN HEART JOURNAL
- Cholesterol, CCR2, and monocyte phenotypes in atherosclerosis
- (2017) Matthias Nahrendorf et al. EUROPEAN HEART JOURNAL
- Lipoprotein(a): the revenant
- (2017) Baris Gencer et al. EUROPEAN HEART JOURNAL
- PCSK9 in chronic kidney disease
- (2017) P. Pavlakou et al. INTERNATIONAL UROLOGY AND NEPHROLOGY
- PCSK9 and infection: A potentially useful or dangerous association?
- (2017) Farzad Khademi et al. JOURNAL OF CELLULAR PHYSIOLOGY
- The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure
- (2017) Antoni Bayes-Genis et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Thyroid stimulating hormone exhibits the impact on LDLR/LDL-c via up-regulating hepatic PCSK9 expression
- (2017) Yingyun Gong et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intensive LDL-cholesterol lowering therapy and neurocognitive function
- (2017) Maciej Banach et al. PHARMACOLOGY & THERAPEUTICS
- Successful treatment of a patient with refractory nephrotic syndrome with PCSK9 inhibitors: a case report
- (2017) Yuki Awanami et al. BMC Nephrology
- PCSK9 regulates apoptosis in human lung adenocarcinoma A549 cells via endoplasmic reticulum stress and mitochondrial signaling pathways
- (2017) Xiaohui Xu et al. Experimental and Therapeutic Medicine
- DENV up-regulates the HMG-CoA reductase activity through the impairment of AMPK phosphorylation: A potential antiviral target
- (2017) Rubén Soto-Acosta et al. PLoS Pathogens
- Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study
- (2017) Massimiliano Ruscica et al. Journal of the American Heart Association
- Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9
- (2017) Kazuhiko Kotani et al. Journal of Thoracic Disease
- Mortality Differences Associated With Treatment Responses in CANTOS and FOURIER
- (2017) Paul M Ridker CIRCULATION
- A Therapeutic Peptide Vaccine Against PCSK9
- (2017) Yajie Pan et al. Scientific Reports
- Liver fat accumulation is associated with circulating PCSK9
- (2016) Massimiliano Ruscica et al. ANNALS OF MEDICINE
- Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?
- (2016) Yajnavalka Banerjee et al. ATHEROSCLEROSIS
- PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study
- (2016) Jin M. Cheng et al. ATHEROSCLEROSIS
- Novel phosphatidylethanolamine derivatives accumulate in circulation in hyperlipidemicApoE−/−mice and activate platelets via TLR2
- (2016) Sudipta Biswas et al. BLOOD
- The Role of Cholesterol in Cancer
- (2016) Omer F. Kuzu et al. CANCER RESEARCH
- Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms
- (2016) Hagai Tavori et al. CARDIOVASCULAR RESEARCH
- The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated HypercholesterolemiaClinical Perspective
- (2016) Mary E. Haas et al. CIRCULATION
- Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome
- (2016) Dirk J. Blom et al. DIABETES OBESITY & METABOLISM
- Increased PCSK9 Cerebrospinal Fluid Concentrations in Alzheimer’s Disease
- (2016) Francesca Zimetti et al. JOURNAL OF ALZHEIMERS DISEASE
- Elevated levels of serum cholesterol are associated with better performance on tasks of episodic memory
- (2016) Elizabeth C. Leritz et al. METABOLIC BRAIN DISEASE
- The anti-dengue virus properties of statins may be associated with alterations in the cellular antiviral profile expression
- (2016) Owen Lloyd Bryan-Marrugo et al. Molecular Medicine Reports
- Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
- (2016) Brian A. Ference et al. NEW ENGLAND JOURNAL OF MEDICINE
- Differential Expression of PCSK9 Modulates Infection, Inflammation, and Coagulation in a Murine Model of Sepsis
- (2016) Dhruva J. Dwivedi et al. SHOCK
- Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes
- (2016) Aarti Ramanathan et al. PLoS One
- PCSK9-deficiency does not alter blood pressure and sodium balance in mouse models of hypertension
- (2015) Jean-Mathieu Berger et al. ATHEROSCLEROSIS
- On the function and homeostasis of PCSK9: Reciprocal interaction with LDLR and additional lipid effects
- (2015) Hagai Tavori et al. ATHEROSCLEROSIS
- Sirtuins in vascular diseases: Emerging roles and therapeutic potential
- (2015) Nunzia D'Onofrio et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Cholesterol lowering: role in cancer prevention and treatment
- (2015) Toshiyuki Murai BIOLOGICAL CHEMISTRY
- Oxidized LDL activates blood platelets through CD36/NOX2-mediated inhibition of the cGMP/protein kinase G signaling cascade
- (2015) S. Magwenzi et al. BLOOD
- Intratumor cholesteryl ester accumulation is associated with human breast cancer proliferation and aggressive potential: a molecular and clinicopathological study
- (2015) David de Gonzalo-Calvo et al. BMC CANCER
- Decreased PCSK9 expression in human hepatocellular carcinoma
- (2015) Mamatha Bhat et al. BMC GASTROENTEROLOGY
- Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials
- (2015) Xin-Lin Zhang et al. BMC Medicine
- Cross-talk between LOX-1 and PCSK9 in vascular tissues
- (2015) Zufeng Ding et al. CARDIOVASCULAR RESEARCH
- Effects of Evolocumab on Vitamin E and Steroid Hormone LevelsNovelty and Significance
- (2015) Dirk J. Blom et al. CIRCULATION RESEARCH
- PCSK9 and its modulation
- (2015) Chuan-Jue Cui et al. CLINICA CHIMICA ACTA
- Relationship between testosterone, estradiol and circulating PCSK9: Cross-sectional and interventional studies in humans
- (2015) T.C. Ooi et al. CLINICA CHIMICA ACTA
- Factoring in Factor VIII With Acute Ischemic Stroke
- (2015) James E. Siegler et al. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
- Lovastatin for the Treatment of Adult Patients With Dengue: A Randomized, Double-Blind, Placebo-Controlled Trial
- (2015) James Whitehorn et al. CLINICAL INFECTIOUS DISEASES
- Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials
- (2015) A. Sahebkar et al. DIABETES OBESITY & METABOLISM
- ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
- (2015) John J.P. Kastelein et al. EUROPEAN HEART JOURNAL
- Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9
- (2015) Quoc-Tuan Le et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Vascular dementia
- (2015) John T O'Brien et al. LANCET
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
- (2015) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Low-density lipoprotein receptor affects the fertility of female mice
- (2015) Tao Guo et al. REPRODUCTION FERTILITY AND DEVELOPMENT
- Identification of PCSK9 as a novel serum biomarker for the prenatal diagnosis of neural tube defects using iTRAQ quantitative proteomics
- (2015) Dong An et al. Scientific Reports
- Proprotein Convertase Subtilisin/Kexin Type 9 Deficiency Reduces Melanoma Metastasis in Liver
- (2015) Xiaowei Sun et al. NEOPLASIA
- Cholesteryl Ester Accumulation Induced by PTEN Loss and PI3K/AKT Activation Underlies Human Prostate Cancer Aggressiveness
- (2014) Shuhua Yue et al. Cell Metabolism
- Proprotein Convertase Subtilisin Kexin Type 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein B Lipoproteins Through Both Low-Density Lipoprotein Receptor–Dependent and –Independent Mechanisms
- (2014) Shirya Rashid et al. CIRCULATION
- Preserved adrenal function in fully PCSK9-deficient subject
- (2014) Bertrand Cariou et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans
- (2014) Ylva Bonde et al. JOURNAL OF LIPID RESEARCH
- Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin
- (2014) Susan Kühnast et al. JOURNAL OF LIPID RESEARCH
- CRISPR-Cas systems for editing, regulating and targeting genomes
- (2014) Jeffry D Sander et al. NATURE BIOTECHNOLOGY
- A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
- (2014) Dirk J. Blom et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ezetimibe – a new approach in hypercholesterolemia management
- (2014) Dariusz Suchy et al. Pharmacological Reports
- Lovastatin Delays Infection and Increases Survival Rates in AG129 Mice Infected with Dengue Virus Serotype 2
- (2014) Marlen Martinez-Gutierrez et al. PLoS One
- Peptide-Based Anti-PCSK9 Vaccines - An Approach for Long-Term LDLc Management
- (2014) Gergana Galabova et al. PLoS One
- PCSK9 is a critical regulator of the innate immune response and septic shock outcome
- (2014) K. R. Walley et al. Science Translational Medicine
- Extrahepatic complications of nonalcoholic fatty liver disease
- (2013) Matthew J. Armstrong et al. HEPATOLOGY
- Identification of a Small Peptide That Inhibits PCSK9 Protein Binding to the Low Density Lipoprotein Receptor
- (2013) Yingnan Zhang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a)
- (2013) Gregor Leibundgut et al. JOURNAL OF LIPID RESEARCH
- Hepatitis C Virus Stimulates Low-Density Lipoprotein Receptor Expression To Facilitate Viral Propagation
- (2013) G. H. Syed et al. JOURNAL OF VIROLOGY
- The global distribution and burden of dengue
- (2013) Samir Bhatt et al. NATURE
- Targeting Toll-Like Receptors: Promising Therapeutic Strategies for the Management of Sepsis-Associated Pathology and Infectious Diseases
- (2013) Athina Savva et al. Frontiers in Immunology
- Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice
- (2012) Maxime Denis et al. CIRCULATION
- PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-κB activation in THP-1-derived macrophages
- (2012) ZHIHAN TANG et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Regulation of Epithelial Sodium Channel Trafficking by Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
- (2012) Vikas Sharotri et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- PCSK9 SNP rs11591147 is associated with low cholesterol levels but not with cognitive performance or noncardiovascular clinical events in an elderly population
- (2012) Iris Postmus et al. JOURNAL OF LIPID RESEARCH
- Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study
- (2012) Robert P Giugliano et al. LANCET
- The biology and therapeutic targeting of the proprotein convertases
- (2012) Nabil G. Seidah et al. NATURE REVIEWS DRUG DISCOVERY
- Dengue
- (2012) Cameron P. Simmons et al. NEW ENGLAND JOURNAL OF MEDICINE
- SILAC-based quantitative proteomic analysis of gastric cancer secretome
- (2012) Arivusudar Marimuthu et al. Proteomics Clinical Applications
- Hepatitis C virus host cell entry
- (2012) Alexander Ploss et al. Current Opinion in Virology
- Induction of brain natriuretic peptide and monocyte chemotactic protein-1 gene expression by oxidized low-density lipoprotein: relevance to ischemic heart failure
- (2011) Aluganti N. Chandrakala et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels
- (2011) Nicola Ferri et al. ATHEROSCLEROSIS
- Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure
- (2011) Fabrice Ivanes et al. EUROPEAN HEART JOURNAL
- Role of low-density lipoprotein receptor in the hepatitis C virus life cycle
- (2011) Anna Albecka et al. HEPATOLOGY
- Novel Domain Interaction Regulates Secretion of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Protein
- (2011) Fen Du et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The Lipogenesis Pathway as a Cancer Target
- (2011) Hanley N. Abramson JOURNAL OF MEDICINAL CHEMISTRY
- PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax–caspase9–caspase3 pathway
- (2011) Chun-Yan Wu et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Low Cholesterol Triggers Membrane Microdomain-dependent CD44 Shedding and Suppresses Tumor Cell Migration
- (2010) Toshiyuki Murai et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Cellular cholesterol delivery, intracellular processing and utilization for biosynthesis of steroid hormones
- (2010) Jie Hu et al. Nutrition & Metabolism
- PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities
- (2009) Majambu Mbikay et al. FEBS LETTERS
- PCSK9 impedes hepatitis C virus infectionin vitroand modulates liver CD81 expression
- (2009) Patrick Labonté et al. HEPATOLOGY
- Genetic and Metabolic Determinants of Plasma PCSK9 Levels
- (2009) Susan G. Lakoski et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Hepatitis C virus cell entry: role of lipoproteins and cellular receptors
- (2009) M. E. Burlone et al. JOURNAL OF GENERAL VIROLOGY
- A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism
- (2009) Robert J. Glynn et al. NEW ENGLAND JOURNAL OF MEDICINE
- C-reactive protein and venous thromboembolism: a prospective investigation in the ARIC cohort
- (2009) Aaron R. Folsom et al. THROMBOSIS AND HAEMOSTASIS
- The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia
- (2008) Jean-Charles Fruchart et al. AMERICAN JOURNAL OF CARDIOLOGY
- Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo
- (2008) Robert J. Schmidt et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide
- (2008) LiXin Shan et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- A Specific CD36-Dependent Signaling Pathway Is Required for Platelet Activation by Oxidized Low-Density Lipoprotein
- (2008) Kan Chen et al. CIRCULATION RESEARCH
- Diabetic dyslipidemia and atherosclerosis: Evidence from clinical trials
- (2008) John A. Farmer Current Diabetes Reports
- Importance of Proprotein Convertase Subtilisin/Kexin Type 9 in the Hormonal and Dietary Regulation of Rat Liver Low-Density Lipoprotein Receptors
- (2008) Lena Persson et al. ENDOCRINOLOGY
- Genome-wide expression analysis of cells expressing gain of function mutant D374Y-PCSK9
- (2008) Trine Ranheim et al. JOURNAL OF CELLULAR PHYSIOLOGY
- A biomarker panel for peripheral arterial disease
- (2008) Eric T Fung et al. VASCULAR MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now